Phase 2 Macular Degeneration Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 50 or older, of any gender.
• People who have been diagnosed with geographic atrophy (a type of vision loss) caused by age-related macular degeneration (AMD) in at least one eye, where the affected area is within a specific size range — not too small and not too large (confirm with trial site for exact measurements).
• If the area of vision loss is made up of multiple patches, at least one patch must meet a minimum size requirement, and the total affected area must still fall within the specified range (confirm with trial site).
• The entire affected area in the eye being studied must be fully visible within a standard eye imaging scan and must not extend into a specific nearby region of the retina (confirm with trial site).
• People whose vision in the study eye is at a level of at least 20/200 on a standard eye chart test.

Who may not be able to join:

• People who have a history of, or currently show signs of, a condition involving abnormal blood vessel growth under the retina (sometimes called "wet" AMD) in either eye, based on imaging reviewed at screening.
• People who have previously received any cell or gene therapy treatment in either eye.
• People whose macular vision loss is caused by a condition other than AMD, such as certain inherited or drug-related eye diseases.
• People who have had eye surgery (including cataract or retinal surgery) in the study eye within the 3 months before the trial's starting point.
• People who have clouding of the eye, uncontrolled eye movements, severely drooping eyelids, restricted eye movement, or head tremor that could interfere with eye imaging quality, as assessed by the treating doctor.

Important: Always verify eligibility with the trial site directly before applying.